Pancreatic Cancer Research

ResearcherSapporo Medical UniversityNo recent work listed

Koichi Hirata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6492-4734; OpenAlex author ID A5101847731. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper

Papers 11

  1. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Co-author DOI 10.1111/cas.14106↗
  2. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Last author DOI 10.1007/s00595-015-1120-8↗
  3. Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. Co-author DOI 10.1038/srep33582↗
  4. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Co-author DOI 10.1002/prp2.196↗
  5. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Co-author DOI 10.18632/oncotarget.3109↗
  6. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells. Co-author DOI 10.3892/ijo.2015.2880↗
  7. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.1093/carcin/bgt057↗
  8. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Last author DOI 10.1111/cas.12046↗
  9. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. Co-author DOI 10.1002/jcb.23095↗
  10. Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4. Co-author DOI 10.1007/s00441-011-1287-2↗
  11. Downregulation of tight junction-associated MARVEL protein marvelD3 during epithelial-mesenchymal transition in human pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2011.06.020↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 8 shared papers, 2011–2019 · strength 0.34
  2. Norimasa Sawada · 6 shared papers, 2011–2016 · strength 0.21
  3. Takashi Kojima · 6 shared papers, 2011–2016 · strength 0.21
  4. Masafumi Imamura · 5 shared papers, 2011–2015 · strength 0.17
  5. Akira Takasawa · 5 shared papers, 2011–2016 · strength 0.16
  6. Daisuke Kyuno · 5 shared papers, 2011–2015 · strength 0.15
  7. Tatsuya Ito · 5 shared papers, 2011–2015 · strength 0.15
  8. Yoshihiko Hirohashi · 3 shared papers, 2013–2019 · strength 0.14
  9. Toshihiko Torigoe · 3 shared papers, 2013–2019 · strength 0.14
  10. Hiroaki Shima · 3 shared papers, 2013–2019 · strength 0.14
  11. Toru Mizuguchi · 2 shared papers, 2016–2019 · strength 0.11
  12. Kohzoh Imai · 2 shared papers, 2015–2019 · strength 0.10
  13. Tsuyoshi Kono · 2 shared papers, 2015–2016 · strength 0.10
  14. Satoshi Wada · 1 shared paper, 2019 · strength 0.07
  15. Ichiro Takemasa · 1 shared paper, 2019 · strength 0.07
  16. Makoto Osanai · 1 shared paper, 2016 · strength 0.05
  17. Yukari Nishii · 1 shared paper, 2015 · strength 0.05
  18. Yuji Sakuma · 1 shared paper, 2015 · strength 0.05
  19. Atsushi Miyamoto · 1 shared paper, 2016 · strength 0.05
  20. Takumi Konno · 1 shared paper, 2015 · strength 0.05
  21. Shinichi Kanno · 1 shared paper, 2015 · strength 0.04
  22. Kei Mitsuhashi · 1 shared paper, 2015 · strength 0.04
  23. Reo Maruyama · 1 shared paper, 2015 · strength 0.04
  24. Hiromu Suzuki · 1 shared paper, 2015 · strength 0.04
  25. Yasushi Adachi · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.